Ischemia modified albumin, high-sensitivity c-reactive protein and natriuretic peptide in patients with coronary atherosclerosis

Clinica Chimica Acta

Volumn 408, Issue 1-2, 2009, Pages 65-69

  Kazanis, Konstantinos ^a   Dalamaga, Maria ^a   Nounopoulos, Charalampos ^a   Manolis, Antonios S ^b   Sakellaris, Nikolaos ^b   Jullien, Gerard ^b   Dionyssiou Asteriou, Amalia ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b EVANGELISMOS HOSPITAL   (Greece)

Author keywords

Albumin; Antioxidant status; Coronary atherosclerosis; High sensitivity C reactive protein; Ischemia modified albumin; Natriuretic peptide

Indexed keywords

ANTIOXIDANT; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; ISCHEMIA MODIFIED ALBUMIN;

ACUTE CORONARY SYNDROME; ADULT; AGE DISTRIBUTION; AGED; ANGIOCARDIOGRAPHY; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; CORRELATION FUNCTION; EARLY DIAGNOSIS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL DOCUMENTATION; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; SEX DIFFERENCE;

ADULT; AGED; AGED, 80 AND OVER; ANTIOXIDANTS; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; FEMALE; HUMANS; MALE; MIDDLE AGED; NATRIURETIC PEPTIDES; NECROSIS; SERUM ALBUMIN; TROPONIN T;

EID: 69849088545     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cca.2009.07.007     Document Type: Article

References (30)

1. Apple F.S., Wu A.H.B., Mair J., et al. Future biomarkers for detection of ischemia and risk stratification in acute coronary syndrome. Clin Chem 51 (2005) 810-824
2. Roy D., Quiles J., Aldama G., et al. Ischemia modified albumin for the assessment of patients presenting to the emergency department with acute chest pain but normal or non-diagnostic 12-lead electrocardiograms and negative cardiac troponin T. Int J Cardiol 97 (2004) 297-301
3. Garrido I.P., Roy D., Calvino R., et al. Comparison of ischemia-modified albumin levels in patients undergoing percutaneous coronary intervention for unstable angina pectoris with versus without coronary collaterals. Am J Cardiol 93 (2004) 88-90
4. 2+ binding amino-acid residues of the N-terminus of human albumin: an insight into the mechanism of a new assay for myocardial ischemia. Eur J Biochem 268 (2001) 42-47
5. Gugliucci A., Hermo R., Monroy C., Numaguchi M., and Kimura S. Ischemia-modified albumin levels in cord blood: a case-control study in uncomplicated and complicated deliveries. Clin Chim Acta 362 (2005) 155-160
6. Christenson R.H., Duh S.H., Sanhai W.R., et al. Characteristics of an albumin cobalt binding test for assessment of acute coronary syndrome patients: a multicenter study. Clin Chem 47 (2001) 464-470
7. Bhagavan N.V., Lai E.M., Rios P.A., et al. Evaluation of human serum albumin cobalt binding assay for the assessment of myocardial ischemia and myocardial infarction. Clin Chem 49 (2003) 581-585
8. Liyan C., Jie Z., Yonghua W., and Xiaozhou H. Assay of ischemia-modified albumin and C-reactive protein for early diagnosis of acute coronary syndromes. J Clin Lab Anal 22 (2008) 45-49
9. Sinha M.K., Gaze D.C., Tippins J.R., Collinson P.O., and Kaski J.C. Ischemia modified albumin is a sensitive marker of myocardial ischemia after percutaneous coronary intervention. Circulation 107 (2003) 2403-2405
10. Borderie D., Allanore Y., Meune C., Devaux J.Y., Ekindjian O.G., and Kahan A. High ischemia-modified albumin concentration reflects oxidative stress but not myocardial involvement in systemic sclerosis. Clin Chem 50 (2004) 2190-2193
11. Naghavi M., Libby P., Falk E., et al. From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: part I. Circulation 108 (2003) 1664-1672
12. Naghavi M., Libby P., Falk E., et al. From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: part II. Circulation 108 (2003) 1772-1778
13. Bar-Or D., Lau E., and Winkler J.V. A novel assay for cobalt albumin binding and its potential as a marker for myocardial ischemia - a preliminary report. J Emerg Med 19 (2000) 311-315
14. Morrow D.A., de Lemos J.A., Sabatine M.S., and Antman E.M. The search for a biomarker of cardiac ischemia. Clin Chem 49 (2003) 537-539
15. Quiles J., Roy D., Gaze D., et al. Relation of ischemia-modified albumin (IMA) levels following elective angioplasty for stable angina pectoris to duration of balloon-induced myocardial ischemia. Am J Cardiol 92 (2003) 322-324
16. Lee Y.W., Kim H.J., Cho Y.H., Shin H.B., Choi T.Y., and Lee Y.K. Application of albumin-adjusted ischemia modified albumin index as an early screening marker for acute coronary syndrome. Clin Chim Acta 384 (2007) 24-27
17. de Winter R.J., Fischer J., Bholasingh R., et al. C-reactive protein and cardiac troponin T in risk stratification: differences in optimal timing of tests early after the onset of chest pain. Clin Chem 46 (2000) 1597-1603
18. Roy D., and Kaski J.C. IMA - the role of oxidative stress. Europace 9 (2007) 854-855
19. Lippi G., Montagnana M., and Guidi G.C. Albumin cobalt binding and ischemia modified albumin generation: an endogenous response to ischemia?. Int J Cardiol 108 (2006) 410-411
20. Xi L., Taher M., Yin C., Salloum F., and Kukreja R.C. Cobalt chloride induces delayed cardiac preconditioning in mice through selective activation of HIF-1alpha and AP-1 and iNOS signaling. Am J Physiol Heart Circ Physiol 287 (2004) H2369-H2375
21. Biomarkers Definition Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 69 (2001) 89-95
22. Vasan R.S. Biomarkers of cardiovascular disease: molecular basis and practical considerations. Circulation 113 (2006) 2335-2362
23. Bar-Or D., Rael L.T., Bar-Or R., et al. The cobalt-albumin binding assay: insights into its mode of action. Clin Chim Acta 387 (2008) 120-127
24. Roche M., Rondeau P., Singh N.R., Tarnus E., and Bourdon E. The antioxidants properties of serum albumin. FEBS Lett 582 (2008) 1783-1787
25. Djousse L., Rothman K.J., Cupples L.A., Levy D., and Ellison R.C. Serum albumin and risk of myocardial infarction and all-cause mortality in the Framingham Offspring Study. Circulation 106 (2002) 2919-2924
26. Delimaris I., Georgopoulos S., Kroupis C., et al. Serum oxidizability, total antioxidant status and albumin serum levels in patients with aneurysmal or arterial occlusive disease. Clin Biochem 41 (2008) 706-711
27. Zapico-Muniz E., Santalo-Bel M., Merce-Muntanola J., Montiel J.A., Martinez-Rubio A., and Ordonez-Llanos J. Ischemia-modified albumin during skeletal muscle ischemia. Clin Chem 50 (2004) 1063-1065
28. Bibbins-Domingo K., Gupta R., Na B., Wu A.H., Shiller N.B., and Whooley M.A. N-terminal fragment of the prohormone brain-type natriuretic peptide (NT-proBNP), cardiovascular events, and mortality in patients with stable coronary heart disease. JAMA 297 (2007) 169-176
29. Ridker P.M. C-reactive protein. A simple test to help predict risk of heart attack and stroke. Circulation 108 (2003) e81-e85
30. Jernberg T., James S., Lindahl B., et al. Natriuretic peptides in unstable coronary artery disease. Eur Heart J 25 (2004) 1486-1493